| Document |
Document Title |
|
WO/2011/119732A2 |
This invention relates generally to integrin ligand discovery and to a method of integrin ligand discovery base upon induction of ligand-induced epitopes. Such ligands have the potential to be active agent as anti-inflammatory, anti-angi...
|
|
WO/2011/116336A1 |
Disclosed is a compound of the formula (I) or a pharmaceutically acceptable salt thereof:(I) in which R1, R2, R3, and R4 are defined herein and pharmaceutical compositions thereof. Further provided is a method of treating various disorde...
|
|
WO/2011/116356A2 |
The disclosure provides compounds and compositions, and methods of using these compounds and compositions, as positive ailosteric modulators of the melabotropic glutamatc subtype 2 (mGlu2) receptor, and for treating CNS disorders associa...
|
|
WO/2011/104203A1 |
The present invention provides the compounds of the general formula (I) in which n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X are each defined as described below, enantiomers thereof, diastereomers thereof, mixtures thereof and ...
|
|
WO/2011/101402A1 |
The present invention relates to compounds formula (I), wherein P is P1, P2, heterocyclyl or heterocyclyl substituted by one to five Z; and wherein A1, A2, A3, A4, G1, R1, R2, R3, R4, R5, R6, R17, R18, R19 and R20 are as defined in claim...
|
|
WO/2011/094953A1 |
A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 and Ar are as defined in description and in claims, can be used as a medicament.
|
|
WO/2011/092287A1 |
The invention relates to substituted ketonic isoxazoline compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to the use of the substitute...
|
|
WO/2011/088015A1 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...
|
|
WO/2011/070136A1 |
The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical composit...
|
|
WO/2011/070539A1 |
Compounds of Formula (II) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C...
|
|
WO/2011/063843A1 |
The invention relates to a method for producing 5,5-disubstituted 2-isoxazolines of formula (I), wherein R1, R2 independently represent C1-C6 alkyl or C1-C4 halogenalkyl; or R1 and R2 together form a C2-C5 alkandiyl chain which can be mo...
|
|
WO/2011/066482A2 |
Processes for the chiral syntheses of isoxazolines and intermediates are described. Compounds prepared thereby, and methods of using the compounds are also described.
|
|
WO/2011/063842A1 |
The invention relates to a method for producing 5,5-disubstituted 4,5-dihydroisoxazol-3-thiocarboxamidine salts of formula (I), characterized in that i) 3-unsubstituted 4,5-dihydroisoxazoles of formula (II) are first reacted with a chlor...
|
|
WO/2011/061271A1 |
The present invention provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the com...
|
|
WO/2011/059042A1 |
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof, which exhibits excellent long chain fatty acid elongase 6 inhibitory activity and is useful for prevention and ...
|
|
WO/2011/059784A1 |
Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor ...
|
|
WO/2011/057956A1 |
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...
|
|
WO/2005/060456A9 |
The present invention relates to methods of treating ADAMTS-S-associated diseases and particularly osteoarthritis comprising administering an agent capable an of modulating ADMATS-5 activity to a subject afflicted with the disease. The a...
|
|
WO/2011/051282A1 |
The present invention relates to (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives having the general formula (I) to pharmaceutical compositions comprising the same and to the use of these (1,1,1,3,3,3-hexafluoro-2-hydroxyp...
|
|
WO/2011/052756A1 |
Disclosed are a GPR40 activator, particularly an insulin secretion promoter, and a prophylactic and/or therapeutic agent for diabetes, obesity, etc. each containing, as an active ingredient, a novel compound having a GPR40 agonistic acti...
|
|
WO/2011/047432A1 |
The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions cont...
|
|
WO/2011/045259A1 |
The present invention relates to aminopropenoate derivatives, their process of preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of ...
|
|
WO/2011/046954A1 |
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...
|
|
WO/2011/041729A2 |
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists...
|
|
WO/2011/041461A2 |
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists...
|
|
WO/2011/041694A2 |
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists...
|
|
WO/2011/041462A2 |
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists...
|
|
WO/2011/038572A1 |
The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, partic...
|
|
WO/2011/037192A1 |
Disclosed is a substituted amide represented by formula (I), which is useful as an active ingredient of a pharmaceutical composition, especially as an active ingredient of a pharmaceutical composition for the treatment of diseases that a...
|
|
WO/2011/033251A1 |
The present invention relates to isoxazoline-oxime derivatives of formula (I); where R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes an...
|
|
WO/2011/027888A1 |
Disclosed are a diamide-phenyl derivative which inhibits soluble epoxy hydrolase (sEH), and a pharmaceutically acceptable salt of the diamide-phenyl derivative. Specifically disclosed are a compound represented by formula (I), and a phar...
|
|
WO/2011/023864A1 |
The invention relates to compounds, in particular MMP inhibitors. The compounds of the invention have formula (1). The invention can be used in particular in the pharmaceutical field. The present invention also relates to labeled compoun...
|
|
WO/2011/020615A1 |
The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the tr...
|
|
WO/2011/020849A1 |
The present invention relates to a pharmaceutical preparation comprising as an active ingredient a primary amide according to the general formula (1) and/or a secondary amide according to the general formula (2) and their use as a medica...
|
|
WO/2011/020907A1 |
The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical composit...
|
|
WO/2011/017299A2 |
A process for preparing 7-[2-[4-(6-fluoro -3-methyl -1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-
7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine
, intermediates useful in that process, and processes for prepa...
|
|
WO/2011/017350A2 |
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists...
|
|
WO/2011/010332A1 |
The invention concerns a process for preparing BTG-1640, i.e. rel- (3R*,3aS*,7aS*)-3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydr
obenzo[d]isoxazol- 4-one or a salt thereof, comprising the following steps: d) adding phenylacetaldehyde (4) ...
|
|
WO/2011/009484A1 |
The present invention provides novel organic compounds of formula (I) or (Ia): which may be inhibitors of a selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example PKD-1/2/3, inhibitors of histon...
|
|
WO/2011/007819A1 |
Disclosed is a compound represented by formula (I) or the like, which is used as an agent for treatment of diseases that are induced by the production, secretion or deposition of amyloid β protein. Specifically disclosed is a pharmaceut...
|
|
WO/2011/003895A1 |
The invention relates to 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives having the general Formula (I) wherein R1 represents the group CONR2R3 which is present at one of the positions 5-, 6- or 7- on the 1,2-benzisoxazole ring; R2 and ...
|
|
WO/2011/001089A1 |
The present invention relates to novel benzenesulfonamide compounds having a structure of formula (I), as well as to the method for synthesizing same and to the use thereof in pharmaceutical compositions to be used in human or veterinary...
|
|
WO/2011/002067A1 |
Disclosed are a heterocyclic derivative which has excellent amyloid β production inhibitory activity, and a use of the heterocyclic derivative. Specifically disclosed is a compound represented by formula (I) or a salt thereof. (In the f...
|
|
WO/2010/147792A2 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...
|
|
WO/2010/142836A1 |
The present invention relates to the synthesis of intermediates that can be used in TTX synthesis and to the preparation thereof.
|
|
WO/2010/142650A1 |
The invention relates to compounds of formula (I) wherein A1, R1, R2, R3, R4 and R5 are defined in the description and in the claims, which are preferential inhibitors of the cysteine protease cathepsin, in particular of the cysteine pro...
|
|
WO/2010/141768A2 |
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists...
|
|
WO/2010/141761A2 |
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists...
|
|
WO/2010/136493A1 |
The present invention provides a compound of formula I' or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the inv...
|
|
WO/2010/135360A1 |
The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical ...
|
